SG11201506493VA - Identifying patient response to s1p receptor modulator administration - Google Patents
Identifying patient response to s1p receptor modulator administrationInfo
- Publication number
- SG11201506493VA SG11201506493VA SG11201506493VA SG11201506493VA SG11201506493VA SG 11201506493V A SG11201506493V A SG 11201506493VA SG 11201506493V A SG11201506493V A SG 11201506493VA SG 11201506493V A SG11201506493V A SG 11201506493VA SG 11201506493V A SG11201506493V A SG 11201506493VA
- Authority
- SG
- Singapore
- Prior art keywords
- receptor modulator
- patient response
- identifying patient
- modulator administration
- administration
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Ecology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361808406P | 2013-04-04 | 2013-04-04 | |
US201361811321P | 2013-04-12 | 2013-04-12 | |
US201361813380P | 2013-04-18 | 2013-04-18 | |
PCT/EP2013/058226 WO2014161606A1 (fr) | 2013-04-04 | 2013-04-19 | Identification de la réponse d'un patient à une administration d'un modulateur de récepteur de s1p |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201506493VA true SG11201506493VA (en) | 2015-10-29 |
Family
ID=48142792
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201506493VA SG11201506493VA (en) | 2013-04-04 | 2013-04-19 | Identifying patient response to s1p receptor modulator administration |
SG10201707826RA SG10201707826RA (en) | 2013-04-04 | 2013-04-19 | Identifying patient response to s1p receptor modulator administration |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201707826RA SG10201707826RA (en) | 2013-04-04 | 2013-04-19 | Identifying patient response to s1p receptor modulator administration |
Country Status (19)
Country | Link |
---|---|
US (4) | US20160046573A1 (fr) |
EP (4) | EP3199947A3 (fr) |
JP (3) | JP6240746B2 (fr) |
KR (1) | KR102166228B1 (fr) |
AR (1) | AR090929A1 (fr) |
AU (3) | AU2013385181A1 (fr) |
BR (1) | BR112015020140A8 (fr) |
CA (2) | CA3149287A1 (fr) |
CL (1) | CL2015002933A1 (fr) |
ES (1) | ES2941941T3 (fr) |
HK (1) | HK1213636A1 (fr) |
IL (2) | IL252497B (fr) |
MX (1) | MX2015014014A (fr) |
PH (1) | PH12015502291A1 (fr) |
RU (1) | RU2015141151A (fr) |
SG (2) | SG11201506493VA (fr) |
TN (1) | TN2015000333A1 (fr) |
TW (1) | TW201438716A (fr) |
WO (1) | WO2014161606A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201506493VA (en) | 2013-04-04 | 2015-10-29 | Novartis Ag | Identifying patient response to s1p receptor modulator administration |
RU2017116740A (ru) | 2014-10-16 | 2018-11-16 | Новартис Аг | Комбинации для лечения рассеянного склероза |
US20180042895A1 (en) | 2015-02-26 | 2018-02-15 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
EP3400211A1 (fr) | 2016-01-04 | 2018-11-14 | Auspex Pharmaceuticals, Inc. | Modulateurs azétidine du récepteur de la sphingosine 1-phosphate |
US11629124B2 (en) | 2017-03-09 | 2023-04-18 | Novartis Ag | Solid forms comprising an oxime ether compound, compositions and methods of use thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY150088A (en) * | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
PT2379069E (pt) * | 2008-12-22 | 2015-07-03 | Novartis Ag | Inalador |
JP2013505983A (ja) * | 2009-09-29 | 2013-02-21 | ノバルティス アーゲー | S1p受容体モジュレーターの投与計画 |
SG11201506493VA (en) | 2013-04-04 | 2015-10-29 | Novartis Ag | Identifying patient response to s1p receptor modulator administration |
-
2013
- 2013-04-19 SG SG11201506493VA patent/SG11201506493VA/en unknown
- 2013-04-19 RU RU2015141151A patent/RU2015141151A/ru unknown
- 2013-04-19 EP EP17157993.1A patent/EP3199947A3/fr not_active Withdrawn
- 2013-04-19 EP EP13717513.9A patent/EP2981819A1/fr not_active Withdrawn
- 2013-04-19 KR KR1020157026787A patent/KR102166228B1/ko active IP Right Grant
- 2013-04-19 WO PCT/EP2013/058226 patent/WO2014161606A1/fr active Application Filing
- 2013-04-19 AU AU2013385181A patent/AU2013385181A1/en not_active Abandoned
- 2013-04-19 CA CA3149287A patent/CA3149287A1/fr active Pending
- 2013-04-19 JP JP2016505716A patent/JP6240746B2/ja active Active
- 2013-04-19 BR BR112015020140A patent/BR112015020140A8/pt not_active IP Right Cessation
- 2013-04-19 EP EP19204477.4A patent/EP3647783B1/fr active Active
- 2013-04-19 EP EP22214476.8A patent/EP4191245A3/fr active Pending
- 2013-04-19 US US14/781,922 patent/US20160046573A1/en not_active Abandoned
- 2013-04-19 MX MX2015014014A patent/MX2015014014A/es unknown
- 2013-04-19 CA CA2900844A patent/CA2900844C/fr active Active
- 2013-04-19 ES ES19204477T patent/ES2941941T3/es active Active
- 2013-04-19 SG SG10201707826RA patent/SG10201707826RA/en unknown
- 2013-04-25 TW TW102114869A patent/TW201438716A/zh unknown
- 2013-05-03 AR ARP130101514A patent/AR090929A1/es unknown
-
2015
- 2015-08-03 TN TN2015000333A patent/TN2015000333A1/en unknown
- 2015-10-02 CL CL2015002933A patent/CL2015002933A1/es unknown
- 2015-10-02 PH PH12015502291A patent/PH12015502291A1/en unknown
-
2016
- 2016-02-12 HK HK16101571.7A patent/HK1213636A1/zh unknown
-
2017
- 2017-04-13 AU AU2017202470A patent/AU2017202470A1/en not_active Abandoned
- 2017-05-24 IL IL252497A patent/IL252497B/en unknown
- 2017-05-25 US US15/605,277 patent/US20170320820A1/en not_active Abandoned
- 2017-11-02 JP JP2017213116A patent/JP2018076316A/ja not_active Withdrawn
-
2018
- 2018-09-20 US US16/136,630 patent/US20190135744A1/en not_active Abandoned
-
2019
- 2019-01-23 JP JP2019009208A patent/JP6934481B2/ja active Active
- 2019-03-25 AU AU2019202036A patent/AU2019202036B2/en active Active
-
2020
- 2020-06-03 US US16/891,898 patent/US20210147354A1/en not_active Abandoned
-
2021
- 2021-07-20 IL IL284999A patent/IL284999A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279408B (en) | An infusion system to prevent the wrong referral of a large number of drugs | |
IL245349A0 (en) | Patient control system | |
HK1221672A1 (zh) | 鼻腔給藥 | |
AU357213S (en) | Patient interface | |
EP2922514A4 (fr) | Interface patient bi-radiale | |
AU353287S (en) | Patient interface | |
DK3639872T3 (da) | Lægemiddeladministrationsanordning | |
AU353289S (en) | Patient interface | |
IL284999A (en) | Identification of the patient's response to administration of a S1P receptor modulator | |
IL268718B (en) | Opioid receptor modulator dosage formulation | |
PT2981325T (pt) | Dispositivo de ligação para sistema de administração de fluidos de tratamento médico | |
EP2902052A4 (fr) | Dispositif d'administration de fluide médical | |
EP2968179A4 (fr) | Formes galéniques pharmaceutiques à libération contrôlée | |
LT3046537T (lt) | Farmacinis angliavandenių preparatas, skirtas terapiniam panaudojimui | |
GB201313356D0 (en) | Therapeutic Intervention | |
DK3071267T3 (da) | Lægemiddeladministrationsanordning med ensrettet kobling | |
UA28330S (uk) | Капсула для лікарського засобу | |
HUE037492T2 (hu) | Egyedi központi chipkártya kezelés | |
GB201309971D0 (en) | Oral medicines syringe | |
AU354913S (en) | Patient interface | |
AU354914S (en) | Patient interface | |
AU353572S (en) | Patient interface | |
GB201317745D0 (en) | Patient resuscitation device | |
TH148781B (th) | สารละลายสำหรับการให้ทางช่องปาก |